Article History
Accepted: 5 February 2021
First Online: 24 February 2021
Declarations
:
: No funding was received for the preparation of this letter.
: Robert P. Giugliano reports grants from Daiichi Sankyo, during the conduct of the study; personal fees from Akcea, Amarin, American College of Cardiology, Boehringer-Ingelheim, Bristol Myers Squibb, CVS Caremark, GlaxoSmithKline, Janssen, Lexicon, Portola, Pfizer, Servier, CryoLife, Esperion, Eli Lilly, Samsung, SAJA Pharmaceuticals, and Dr. Reddy’s Laboratories, grants from Anthos, grants and personal fees from Merck, Amgen, and Daiichi Sankyo, outside the submitted work; and an institutional research grant to the TIMI Study Group at Brigham and Women's Hospital for research he is not directly involved in from Abbott; Aralez; AstraZeneca; Bayer; Eisai; GlaxoSmithKline; Intarcia; Janssen Research and Development; Medicines Company; MedImmune; Novartis; Poxel; Quark Pharmaceuticals; Roche; Takeda; Zora Biosciences. Takeshi Yamashita reports grants and personal fees from Daiichi Sankyo, Bristol-Myers Squibb, and Bayer, personal fees from Ono Pharmaceutical and Toa Eiyo, outside the submitted work. Raffaele De Caterina reports grants, personal fees, and non-financial support from Daiichi Sankyo during the conduct of the study; grants and personal fees from Boehringer Ingelheim, BMS/Pfizer, Novartis, and Portola, grants, personal fees, and non-financial support from Bayer, Daiichi Sankyo, Menarini, and AstraZeneca, outside the submitted work, and personal fees from Roche.
: Not applicable.
: Not Applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors assisted with the preparation of the letter and read and approved the final version.